Review ArticleContinuing Education
18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications
Geraldine J. Liao, Amy S. Clark, Erin K. Schubert and David A. Mankoff
Journal of Nuclear Medicine August 2016, 57 (8) 1269-1275; DOI: https://doi.org/10.2967/jnumed.116.175596
Geraldine J. Liao
1Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Amy S. Clark
2Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and
Erin K. Schubert
3Division of Nuclear Medicine, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
David A. Mankoff
3Division of Nuclear Medicine, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 8
August 1, 2016
18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications
Geraldine J. Liao, Amy S. Clark, Erin K. Schubert, David A. Mankoff
Journal of Nuclear Medicine Aug 2016, 57 (8) 1269-1275; DOI: 10.2967/jnumed.116.175596
Jump to section
- Article
- Abstract
- 18F-FES STRUCTURE, SYNTHESIS, PHARMACOKINETICS, AND SAFETY
- CORRELATION OF 18F-FES UPTAKE AND TUMOR ER EXPRESSION
- BASELINE 18F-FES UPTAKE AS A PREDICTOR OF RESPONSE TO ENDOCRINE THERAPY
- ABILITY OF 18F-FES PET TO ASSESS WHOLE-BODY TUMOR BURDEN AND HETEROGENEITY OF DISEASE
- UTILITY OF 18F-FES PET IN ASSESSING IN VIVO PHARMACODYNAMICS
- NON–BREAST CANCER USES OF 18F-FES
- POTENTIAL CLINICAL USES
- CONCLUSION
- Acknowledgments
- Footnotes
- REFERENCES
- Figures & Data
- Supplemental
- Info & Metrics
Related Articles
Cited By...
- 18F-FES Whole-Body Imaging Protocol for Evaluating Tumor Estrogen Receptor Status in Patients with Recurrent or Metastatic Breast Cancer
- Biodistribution of 18F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader
- Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology
- SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
- Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes
- Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer
- Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer
- 18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT
- Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors